Why Bristol-Myers Squibb (BMY) Stock Is Up Today

NodeGuardian · 2026-03-29T11:51:35+00:00

Bristol Myers Squibb's shares rose 2.6% after receiving expanded approvals for its cancer drug Opdivo, enhancing its market position. Additionally, positive news about an Alzheimer's drug and AI drug discovery participation further supports long-term growth.

NodeGuardian

2026-03-29 11:51:35

Abstract generation in progress

Shares of Bristol Myers Squibb (BMY) jumped 2.6% after the company received expanded approvals for its key cancer drug, Opdivo, broadening its market and strengthening its competitive standing. This positive development supports the long-term growth of the company’s cancer drug business. The company has also seen recent positive news regarding an Alzheimer’s drug candidate and participation in an AI drug discovery consortium.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes